216 related articles for article (PubMed ID: 12172336)
21. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.
Halling J; Weihe P; Brosen K
Br J Clin Pharmacol; 2008 Jan; 65(1):134-8. PubMed ID: 17764479
[TBL] [Abstract][Full Text] [Related]
22. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Ford GA; Wood SM; Daly AK
Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
[TBL] [Abstract][Full Text] [Related]
23. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
de Leon J
J Clin Psychopharmacol; 2007 Jun; 27(3):241-5. PubMed ID: 17502769
[No Abstract] [Full Text] [Related]
24. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
25. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.
de Vos A; van der Weide J; Loovers HM
Pharmacogenomics J; 2011 Oct; 11(5):359-67. PubMed ID: 20531370
[TBL] [Abstract][Full Text] [Related]
26. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers.
Tamminga WJ; Wemer J; Oosterhuis B; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2001 Dec; 57(10):717-22. PubMed ID: 11829201
[TBL] [Abstract][Full Text] [Related]
27. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
[TBL] [Abstract][Full Text] [Related]
28. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population.
Yamada H; Dahl ML; Lannfelt L; Viitanen M; Winblad B; Sjöqvist F
Eur J Clin Pharmacol; 1998 Aug; 54(6):479-81. PubMed ID: 9776439
[TBL] [Abstract][Full Text] [Related]
29. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A
Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
[TBL] [Abstract][Full Text] [Related]
31. The interplay between pharmacogenetics, concomitant drugs and blood levels of amitriptyline and its main metabolites.
Mifsud Buhagiar L; Casha M; Grech A; Serracino Inglott A; LaFerla G
Per Med; 2022 Mar; 19(2):113-123. PubMed ID: 35118877
[TBL] [Abstract][Full Text] [Related]
32. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles.
Suzuki Y; Shioiri T; Muratake T; Kawashima Y; Sato S; Hagiwara M; Inoue Y; Shimoda K; Someya T
Eur J Clin Pharmacol; 2003 Apr; 58(12):829-33. PubMed ID: 12698310
[TBL] [Abstract][Full Text] [Related]
33. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
[TBL] [Abstract][Full Text] [Related]
34. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia.
Griese EU; Ilett KF; Kitteringham NR; Eichelbaum M; Powell H; Spargo RM; LeSouef PN; Musk AW; Minchin RF
Pharmacogenetics; 2001 Feb; 11(1):69-76. PubMed ID: 11207032
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
36. Factors Affecting Steady-state Plasma Concentrations of Enantiomeric Mirtazapine and its Desmethylated Metabolites in Japanese Psychiatric Patients.
Hayashi Y; Watanabe T; Aoki A; Ishiguro S; Ueda M; Akiyama K; Kato K; Inoue Y; Tsuchimine S; Yasui-Furukori N; Shimoda K
Pharmacopsychiatry; 2015 Nov; 48(7):279-85. PubMed ID: 26595747
[TBL] [Abstract][Full Text] [Related]
37. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping.
de Leon J; Susce MT; Johnson M; Hardin M; Maw L; Shao A; Allen AC; Chiafari FA; Hillman G; Nikoloff DM
CNS Spectr; 2009 Jan; 14(1):19-34. PubMed ID: 19169185
[TBL] [Abstract][Full Text] [Related]
38. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
[TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
40. Metabolism of amitriptyline with CYP2D6 expressed in a human cell line.
Coutts RT; Bach MV; Baker GB
Xenobiotica; 1997 Jan; 27(1):33-47. PubMed ID: 9041677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
